JP2024531915A5 - - Google Patents

Info

Publication number
JP2024531915A5
JP2024531915A5 JP2024506691A JP2024506691A JP2024531915A5 JP 2024531915 A5 JP2024531915 A5 JP 2024531915A5 JP 2024506691 A JP2024506691 A JP 2024506691A JP 2024506691 A JP2024506691 A JP 2024506691A JP 2024531915 A5 JP2024531915 A5 JP 2024531915A5
Authority
JP
Japan
Prior art keywords
cdr
seq
antigen
muc4
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531915A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/039390 external-priority patent/WO2023014863A1/en
Publication of JP2024531915A publication Critical patent/JP2024531915A/ja
Publication of JP2024531915A5 publication Critical patent/JP2024531915A5/ja
Pending legal-status Critical Current

Links

JP2024506691A 2021-08-05 2022-08-04 抗グリコmuc抗体およびその使用 Pending JP2024531915A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163229839P 2021-08-05 2021-08-05
US63/229,839 2021-08-05
US202163241837P 2021-09-08 2021-09-08
US63/241,837 2021-09-08
US202163270642P 2021-10-22 2021-10-22
US63/270,642 2021-10-22
PCT/US2022/039390 WO2023014863A1 (en) 2021-08-05 2022-08-04 Anti-glyco-muc4 antibodies and their uses

Publications (2)

Publication Number Publication Date
JP2024531915A JP2024531915A (ja) 2024-09-03
JP2024531915A5 true JP2024531915A5 (cg-RX-API-DMAC7.html) 2026-02-20

Family

ID=83189120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506691A Pending JP2024531915A (ja) 2021-08-05 2022-08-04 抗グリコmuc抗体およびその使用

Country Status (8)

Country Link
US (1) US20250101126A1 (cg-RX-API-DMAC7.html)
EP (1) EP4380604A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024531915A (cg-RX-API-DMAC7.html)
KR (1) KR20240107093A (cg-RX-API-DMAC7.html)
AU (1) AU2022324456A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228178A1 (cg-RX-API-DMAC7.html)
TW (1) TW202325726A (cg-RX-API-DMAC7.html)
WO (1) WO2023014863A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202448960A (zh) * 2023-02-07 2024-12-16 美商Go治療公司 包括抗醣MUC4抗體及MIC蛋白α1-α2結構域之抗體融合蛋白及其用途

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104E (cg-RX-API-DMAC7.html)
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5006459A (en) 1986-03-31 1991-04-09 T Cell Sciences, Inc. Therapeutic and diagnostic methods using soluble T cell surface molecules
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001066149A2 (en) 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7105657B2 (en) * 2002-11-08 2006-09-12 Board Of Regents Of The University Of Nebraska Compositions and methods for inhibiting pancreatic cancer metastasis
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
AU2003295471B2 (en) 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディとその使用
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
CN101370927A (zh) 2005-12-07 2009-02-18 基因特伦尼克斯公司 可变容积电穿孔室以及其方法
MX2008009956A (es) 2006-02-02 2008-12-12 Syntarga Bv Analogos de cc-1065 solubles en agua y sus conjugados.
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス, インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
US9588121B2 (en) * 2009-11-06 2017-03-07 Go Therapeutics, Inc. Method for early detection of cancer
EP2511718B1 (en) 2009-12-07 2017-07-05 Ntt Docomo, Inc. Propagation path estimation method, program, and device
US20150165065A1 (en) 2009-12-31 2015-06-18 Avidbiotics Corp. Non-natural mic proteins
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
US8785604B2 (en) 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
DK2707031T3 (da) 2011-05-08 2019-10-07 Legochem Biosciences Inc Protein-active agent conjugates and method for preparing the same
WO2012170470A1 (en) * 2011-06-06 2012-12-13 Board Of Regents Of The University Of Nebraska Compositions and methods for detection and treatment of cancer
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
WO2013096901A1 (en) 2011-12-23 2013-06-27 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
BR112014020502A2 (pt) 2012-02-22 2019-09-24 Univ Pennsylvania sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
US20150191543A1 (en) 2012-08-06 2015-07-09 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
AU2014233478A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
JP2016538877A (ja) 2013-10-14 2016-12-15 シンアフィックス ビー.ブイ. 修飾糖タンパク質、タンパク質コンジュゲート及びそれらの調製方法
WO2015057064A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
WO2015057066A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
WO2015057065A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
EP3097200A1 (en) 2014-01-24 2016-11-30 SynAffix B.V. Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
WO2015119180A1 (ja) * 2014-02-06 2015-08-13 医化学創薬株式会社 ムチン4(muc4)糖ペプチドに対する抗体及びその用途
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
EP3177633B1 (en) 2014-08-04 2022-07-20 SynAffix B.V. Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
EP3733209A1 (en) 2014-10-03 2020-11-04 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
US11117969B2 (en) 2014-12-05 2021-09-14 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands
LT3227311T (lt) 2014-12-05 2022-02-25 Xyphos Biosciences Inc. Įterpiami variabilūs antikūnų fragmentai ir nkg2d ligandų modifikuoti a1-a2 domenai
CN107810273B (zh) 2015-04-23 2022-09-27 西纳福克斯股份有限公司 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法
PE20180188A1 (es) 2015-05-08 2018-01-23 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
HUE067376T2 (hu) 2015-08-04 2024-10-28 Xyphos Biosciences Inc Antitestek beilleszthetõ változó fragmentumai és NKG2D ligandumok módosított a1-a2 doménjei, valamint nem természetes NKG2D receptorokat megkötõ nem természetes NKG2D ligandumok
WO2017051254A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
WO2017051249A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
HUE067016T2 (hu) 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
JP7120765B2 (ja) 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ, インク. ペプチド基を含む複合体及びそれに関連する方法
CN107847605B (zh) 2015-11-25 2021-12-24 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
DK3390450T3 (da) 2015-12-15 2021-03-01 Ose Immunotherapeutics Anti-cd28-humaniserede antistoffer formuleret til indgivelse til mennesker
WO2017137457A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
WO2017137456A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
US10874746B2 (en) 2016-02-08 2020-12-29 Synaffix B.V. Sulfamide linkers for use in bioconjugates
EP3475300A2 (en) 2016-06-24 2019-05-01 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
BR112019012937A2 (pt) 2016-12-23 2019-12-10 Heidelberg Pharma Research Gmbh novo conjugado de amanitina
WO2018182341A1 (ko) 2017-03-29 2018-10-04 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
CN110997013B (zh) 2017-07-24 2022-09-20 瑞泽恩制药公司 抗cd8抗体和其用途
MA52206A (fr) 2018-03-27 2021-02-17 Xyphos Biosciences Inc Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels
EP3773740A1 (en) 2018-04-13 2021-02-17 Heidelberg Pharma Research GmbH Targeted amatoxin conjugate for the treatment of solid tumors
CN110818802B (zh) 2018-08-08 2022-02-08 华夏英泰(北京)生物技术有限公司 一种嵌合t细胞受体star及其应用
US20200147175A1 (en) * 2018-11-10 2020-05-14 Consejo Nacional De Investigaciones Científicas Y Técnicas Method for treating anti-her2 therapy-resistant muc4+ her2+ cancer
US20220096641A1 (en) 2019-01-03 2022-03-31 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
CA3129868A1 (en) 2019-03-01 2020-09-10 Mercy Bioanalytics, Inc. Systems, compositions, and methods for target entity detection
US20220226496A1 (en) 2019-05-02 2022-07-21 Legochem Biosciences, Inc. Ligand-drug conjugate including linker having tris structure
CN114630838A (zh) 2019-05-20 2022-06-14 法国国家健康和医学研究院 新的抗cd25抗体
US20200370013A1 (en) 2019-05-20 2020-11-26 The Trustees Of The University Of Pennsylvania Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
BR112022013008A2 (pt) 2019-12-31 2022-09-06 Legochem Biosciences Inc Composto derivado de pirrolobenzodiazepina, conjugado de derivado-ligante de pirrolobenzodiazepina, e, composição farmacêutica e método para prevenção ou tratamento de doença proliferativa

Similar Documents

Publication Publication Date Title
TWI701259B (zh) 4﹘1bb抗體及其製備方法和應用
TWI805121B (zh) 抗SIRPα抗體及其用途
JP2023511774A5 (cg-RX-API-DMAC7.html)
JP7641967B2 (ja) ヒト化cldn18.2抗体
JP2024001073A5 (cg-RX-API-DMAC7.html)
JP2019116474A5 (cg-RX-API-DMAC7.html)
JP2018502050A5 (cg-RX-API-DMAC7.html)
JP2019531725A5 (cg-RX-API-DMAC7.html)
JP2013500703A5 (cg-RX-API-DMAC7.html)
JP2018522545A (ja) ヘテロ二量体多重特異性抗体フォーマット
RU2015111708A (ru) Способ получения и отбора молекул, включающих по меньшей мере две различные группировки и их применение
IL305951A (en) Anti-nectin-4 antibodies and their uses
JP2010502183A5 (cg-RX-API-DMAC7.html)
JP2021529524A5 (cg-RX-API-DMAC7.html)
JP2023553697A (ja) グリピカン-3およびt細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
JP2023508174A5 (cg-RX-API-DMAC7.html)
KR20200013233A (ko) 신규 항 cd3 항체
JP2024509910A5 (cg-RX-API-DMAC7.html)
JP2020522475A5 (cg-RX-API-DMAC7.html)
JP2023549555A5 (cg-RX-API-DMAC7.html)
IL315960A (en) Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
JP2024534109A (ja) Egfr及びher3を標的とする二重特異性四価抗体
CN119213023A (zh) Ilt3和cd3结合剂以及其使用方法
JP2022523145A5 (cg-RX-API-DMAC7.html)
CN113727731B (zh) 靶向pd-1和lag-3的双特异性抗体